SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes

Similar Items

• SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
  by: Bartosz Rolek, et al.
  Published: (2023-07-01)
• Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
  by: Agata Winiarska, et al.
  Published: (2021-10-01)
• Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
  by: Panagiotis I. Georgianos, et al.
  Published: (2022-02-01)
• Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
  by: Apurva Khedagi, et al.
  Published: (2023-03-01)
• Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
  by: Rahul S. Dadwani, et al.
  Published: (2023-07-01)